VANOS (fluocinonide) Cream, 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluocinonide has the chemical name 6 alpha, 9 alpha-difluoro-11 beta, 21-dihydroxy-16 alpha, 17 alpha-isopropylidenedioxypregna-1, 4-diene-3,20-dione 21-acetate.
VANOS (fluocinonide) Cream, 0.1%, is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older (See PRECAUTIONS: Pediatric Use).
Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g/week because the safety of VANOS Cream for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Therapy should be discontinued when control of the disease is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Do not use more than half of the 120 g tube per week.
Media Articles Related to Vanos (Fluocinonide Topical)
Advances in Psoriasis
Source: Medscape Allergy & Clinical Immunology Headlines [2017.03.16]
This review summarizes traditional as well as new psoriasis treatments and those currently in development. How do these agents fit into clinical practice?
Southern Medical Journal
Psoriasis Responds After Biologic Failure
Source: MedPage Today Dermatology [2017.03.06]
(MedPage Today) -- PASI-75 rate exceeds 80% with tildrakizumab
Cimzia Passes Muster in Two Psoriasis Trials
Source: MedPage Today Dermatology [2017.03.06]
(MedPage Today) -- Met primary efficacy goals versus placebo; third trial still to come
One Biologic Bests Another in Head-to-Head Psoriasis Trial
Source: MedPage Today Dermatology [2017.03.05]
(MedPage Today) -- Taltz turns in better results than Stelara on severity indices
Immune Disorders Such as MS, Psoriasis May Be Tied to Dementia Risk
Source: MedicineNet Dementia Specialty [2017.03.02]
Title: Immune Disorders Such as MS, Psoriasis May Be Tied to Dementia Risk
Category: Health News
Created: 3/1/2017 12:00:00 AM
Last Editorial Review: 3/2/2017 12:00:00 AM
Published Studies Related to Vanos (Fluocinonide Topical)
Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. [2011.02]
OBJECTIVE: To determine the effect a novel formulation of fluocinonide cream on skin barrier function in subjects with atopic dermatitis... CONCLUSION: The authors have shown that short-term treatment with a novel formulation of 0.1% fluocinonide led to significantly improved barrier function as measured by basal TEWL in subjects with active moderate to severe AD. These data suggest short-term treatment with AD with a super-potent corticosteroid improves skin barrier function.
An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. [2006.12]
OBJECTIVE: To assess the potential of a superhigh-potency 0.1% fluocinonide cream to suppress the hypothalamic-pituitary-adrenal (HPA) axis in pediatric patients with atopic dermatitis... CONCLUSIONS: Once-daily treatment with 0.1% fluocinonide cream for 2 weeks does not result in HPA axis suppression under the conditions of this study. Once-daily applications provided similar or better efficacy as twice-daily applications with a lower risk of HPA axis suppression. The frequency of HPA axis suppression is no greater in younger children than in older children. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN71227633.
Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier
function in atopic dermatitis. 
skin barrier function in subjects with atopic dermatitis... CONCLUSION: The authors have shown that short-term treatment with a novel
Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis. [2010.10]
Variations in adherence may cause variations in treatment outcomes with topical corticosteroid therapy for atopic dermatitis...
The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison. [2009.08]
BACKGROUND: This study compared the efficacy of a novel, topical class I synthetic, 0.10% fluocinonide corticosteroid with two other class I corticosteroids and placebo for the treatment of plaque psoriasis... CONCLUSION: The three class I corticosteroid products were comparably effective, numerically and statistically, in clearing the psoriatic plaques. Upon completion of treatment, 60-80% of active-treated sites were clear or almost clear of psoriasis compared to zero with the placebo.
Clinical Trials Related to Vanos (Fluocinonide Topical)
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis [Recruiting]
The purpose of this study is to assess the efficacy and tolerability of short-term treatment
with fluocinonide cream 0. 1% (Vanos®) in the treatment of atopic dermatitis (AD). Our
hypothesis is that subjects will have a reduction in Investigator's Global Assessment scores
at Day 7 and Day 14 compared to Baseline.
Secondary objectives include the use of actigraphy monitoring to determine the ability of
Vanos® cream to reduce itch, and thus nocturnal scratching, in AD. Our hypothesis is that
subjects will have a reduction in nocturnal scratching activity, as measured by actigraphy
movement count per hour, at Day 7 and Day 14 compared to Baseline. Other secondary outcome
measures include Eczema Area and Severity Index (EASI) score, body surface area involvement,
Visual Analog Scale for itch, and Subject Global Assessment. The investigators hypothesize
that each of these measures will be improved at Day 7 and Day 14 compared to Baseline.
Medication adherence will be determined using objective adherence monitors. The
investigators also hypothesize that subjects will have improved adherence to a topical
medication for AD, compared to published sources, if they are only required to use the
medication for a short and defined duration.
Effectiveness of Imiquimod 3.75% Topical Cream Compared to Vanos Cream 0.1% in Subjects With Early Stage Cutaneous T-cell Lymphoma [Not yet recruiting]
This study is being conducted by the Department of Dermatology at the University of
Rochester. The purpose of this study is to determine safety, effectiveness, and tolerability
of two topical therapies, imiquimod and fluocinonide, for patients with early stage
Cutaneous T-cell Lymphoma (CTCL).
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy [Recruiting]
This phase II trial studies how well giving fluocinonide cream works in treating symptoms of
vaginal dryness and painful sexual intercourse in patients with breast cancer undergoing
hormone therapy. Fluocinonide cream may prevent or lessen vaginal dryness and painful sexual
intercourse in patients undergoing hormone therapy.
VANOS Cream and Skin Barrier Function [Recruiting]
The purpose of this study is to determine the effect of short-term therapy using "VANOS
Cream," a super-potent topical steroid cream on skin barrier function in patients with
atopic dermatitis. This cream is already approved for this indication, but the
investigators will further examine its effects on the skin barrier. This cream is a novel
formulation of fluocinonide designed to enhance compliance with a cream base, but have the
skin barrier repair properties of an ointment.
Using an Internet Study to Improve Adherence for Psoriasis Patients [Recruiting]
To evaluate whether participation in an Internet-based intervention helps improve short-term
and long-term psoriasis treatment outcomes, in particular, adherence.